DR. JUAN DE BORB”N
President Global Strategy
Juan de Borbon y de Rojas Sandoval, is a Spanish-American clinical research executive with an extensive
background in Global Clinical R&D conducting over 2000 clinical trials spread across various therapeutic
areas: Neurology, Cardiology, Infectious Disease (Covid-19, Influenza, HIV, HEP B & C, and Ebola),
Nephrology, Hepatology, and Oncology. Jon, using his deep industry knowledge, has motivated, and
inspired the clinical drug development industry for more than two decades now. As a top-ranked
executive recognized by the industry, his employers, and colleagues for his contributions and exemplary
leadership. He is an empathic leader, embracing values of integrity, honesty, and innovation.
Principal Of American Health
His executive experience includes being the President & CEO at Paradigm Clinical Research Institute, a startup business with a focused hospital-based phase 1 clinical pharmacology unit with additional outpatient clinical sites. He has been associated with WCCT Global since 2008, as President and CEO (2016-2018), President and COO (2014-2016), COO (2008-2014) and Managing Director of European Division (2016-2018) in Voorhout, NLD, and President of Medelis / WCCT Oncology (2016-2018). Jon served as COO & Sr. Vice President of Clinical Services & Support at OmniComm Systems an Electronic Data Capture (EDC) software development company. In addition to his regular duties as COO of a publicly traded company he managed global teams that designed, implemented, and supported all clinical trial management (EDC) systems. Before working for OmniComm, he served as the Executive Director of Clinical Operations at PharmaNet Development Group, Inc., responsible for managing a 500+ bed unit including a specialized 50-bed QTc / Critical Care research unit with well over 700 employees.
Juan is the Executive Chairman of the Board – BDA Holdings, Co-Chairman of the Board – Paradigm Clinical Research Institute, Chairman of the Board – National Institute of Health and Longevity, Executive Board Member – BorbÛn Family Office, Advisory Board Member – Life Sciences Institute of New Jersey, Board Member – WCCT Global, Board Member – WCCT Europe, Board Member ñ Medelis Inc., and Board Member – Lamb Pharmaceuticals Inc. In 2017 he created the industryís first American Heart Training Center within a clinical research center to ensure staff training in acute care is at the highest possible standards. In 2016, he merged WCCT with Medelis, an oncology clinical research organization. The intent of the merger was to solve the complex and rapidly growing oncology drug development market in the U.S., Europe, and Asia. This required a unique solution, with insight and expertise and an eye toward the future, we accomplished with our merger.